Highlights
- Market Cap
- $16.90M
- Enterprise Value
- -$404.37M
- EPS (TTM)
- -$51.67
- Total Revenue (TTM)
- $537.82M
- Gross Profit (TTM)
- $401.55M
- EBITDA (TTM)
- -$26.17M
- Year Range
- $2.18 - $41.72
- ROA (TTM)
- -6.72%
- ROE (TTM)
- -10.29%
Share Price Chart
Loading graphics...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
Performance Chart
The chart shows the growth of an initial investment of $10,000 in Burning Rock Biotech Limited, comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.
Loading graphics...
Returns By Period
Burning Rock Biotech Limited (BNR) has returned -19.95% so far this year and 258.45% over the past 12 months.
Burning Rock Biotech Limited
- 1D
- 0.81%
- 1M
- -37.55%
- YTD
- -19.95%
- 6M
- 86.47%
- 1Y
- 258.45%
- 3Y*
- -16.89%
- 5Y*
- -44.00%
- 10Y*
- —
Benchmark (S&P 500 Index)
- 1D
- 2.91%
- 1M
- -5.09%
- YTD
- -4.63%
- 6M
- -2.39%
- 1Y
- 16.33%
- 3Y*
- 16.69%
- 5Y*
- 10.18%
- 10Y*
- 12.16%
Monthly Returns
Based on dividend-adjusted daily data since Jun 12, 2020, BNR's average daily return is -0.01%, while the average monthly return is +0.03%. At this rate, your investment would double in approximately 192.6 years.
Historically, 40% of months were positive and 60% were negative. The best month was Nov 2024 with a return of +119.2%, while the worst month was May 2022 at -56.4%. The longest winning streak lasted 4 consecutive months, and the longest losing streak was 7 months.
On a daily basis, BNR closed higher 45% of trading days. The best single day was Jul 23, 2025 with a return of +41.4%, while the worst single day was Mar 13, 2026 at -29.9%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 69.03% | -24.16% | -37.55% | -19.95% | |||||||||
| 2025 | -1.04% | -5.54% | -28.69% | -35.11% | 6.16% | 1.94% | 82.28% | 50.87% | -0.46% | 55.61% | 60.40% | -6.67% | 198.52% |
| 2024 | -7.53% | -0.90% | -14.57% | 3.71% | -5.31% | -9.83% | 14.16% | -28.06% | -38.34% | -13.94% | 119.22% | 9.58% | -27.42% |
| 2023 | 29.33% | 12.03% | -13.80% | 10.68% | -16.08% | -17.62% | -16.28% | -24.72% | -28.41% | -1.67% | -12.98% | 12.05% | -58.67% |
| 2022 | -5.56% | -6.33% | 10.20% | -40.69% | -56.44% | 21.25% | 9.62% | 22.88% | -39.03% | -13.81% | 21.84% | -10.36% | -76.39% |
| 2021 | 30.61% | 19.29% | -25.20% | 13.30% | -11.25% | 8.83% | -22.67% | -18.22% | -4.03% | -21.20% | 9.72% | -38.36% | -58.74% |
Benchmark Metrics
Burning Rock Biotech Limited has an annualized alpha of -16.27%, beta of 1.02, and R² of 0.03 versus S&P 500 Index. Calculated based on daily prices since June 15, 2020.
- This stock participated in 189.31% of S&P 500 Index downside but only -13.28% of its upside — more exposed to losses than it benefited from rallies.
- R² of 0.03 means this stock moves largely independently of S&P 500 Index — capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- -16.27%
- Beta
- 1.02
- R²
- 0.03
- Upside Capture
- -13.28%
- Downside Capture
- 189.31%
Return for Risk
Risk / Return Rank
BNR ranks 89 for risk / return — in the top 89% of stocks on our site. This means strong returns relative to risk — exactly what professional investors look for. Well-suited for investors who want to maximize return per unit of risk.
Return / Risk — by metrics
The table below present risk-adjusted performance metrics for Burning Rock Biotech Limited (BNR) and compare them to a chosen benchmark (S&P 500 Index).
| BNR | Benchmark | Difference | |
|---|---|---|---|
Sharpe ratioReturn per unit of total volatility | 1.91 | 0.90 | +1.02 |
Sortino ratioReturn per unit of downside risk | 2.81 | 1.39 | +1.42 |
Omega ratioGain probability vs. loss probability | 1.35 | 1.21 | +0.14 |
Calmar ratioReturn relative to maximum drawdown | 4.21 | 1.40 | +2.81 |
Martin ratioReturn relative to average drawdown | 9.86 | 6.61 | +3.25 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Explore BNR risk-adjusted metrics in detail
Dive deeper into individual metrics with historical trends, benchmark comparisons, and performance across different time periods.
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading graphics...
Worst Drawdowns
The table below displays the maximum drawdowns of the Burning Rock Biotech Limited. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Burning Rock Biotech Limited was 99.41%, occurring on May 7, 2025. The portfolio has not yet recovered.
The current Burning Rock Biotech Limited drawdown is 95.92%.
Depth | Start | To Bottom | Bottom | To Recover | End | Total |
|---|---|---|---|---|---|---|
| -99.41% | Feb 23, 2021 | 1057 | May 7, 2025 | — | — | — |
| -39.33% | Jun 24, 2020 | 54 | Sep 9, 2020 | 89 | Jan 15, 2021 | 143 |
| -25.28% | Jan 22, 2021 | 4 | Jan 27, 2021 | 17 | Feb 22, 2021 | 21 |
| -5.77% | Jun 15, 2020 | 1 | Jun 15, 2020 | 3 | Jun 18, 2020 | 4 |
| -1.38% | Jan 20, 2021 | 1 | Jan 20, 2021 | 1 | Jan 21, 2021 | 2 |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading graphics...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Burning Rock Biotech Limited over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how Burning Rock Biotech Limited is priced in the market compared to other companies in the Diagnostics & Research industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for BNR relative to other companies in the Diagnostics & Research industry. Currently, BNR has a P/S ratio of 0.0. This P/S ratio is low compared to the industry average. It may indicate that the stock is undervalued relative to its revenue, or that the market expects slower growth or lower margins.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for BNR in comparison with other companies in the Diagnostics & Research industry. Currently, BNR has a P/B value of 0.0. This P/B ratio is low compared to industry peers. It might indicate the stock is undervalued or that the company’s assets are not expected to generate strong returns.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |